{"transactions":[{"id":3885568,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165545,"kind":"person","name":"CHAPLIN DAVID","position":1,"cik":"0001167232","reported_name":"CHAPLIN DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:10.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Dr. Chaplin's continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039167","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039167/doc4.xml","form_type":"4"}},{"id":4491431,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165545,"kind":"person","name":"CHAPLIN DAVID","position":1,"cik":"0001167232","reported_name":"CHAPLIN DAVID","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-13T22:01:15.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":262500,"price":0.375,"value":98437.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in forty-eight equal monthly installments beginning one month after the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer."}],"balance_after":262500,"derivative":{"exercise_price":0.375,"expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0001209191-17-003700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117003700/doc4.xml","form_type":"4"}}]}